Recognition highlights GeneDx’s leadership in moving genomic medicine to the forefront of healthcare
Published in Genetics in Medicine, study shows broad inpatient implementation of rapid genome sequencing significantly increased diagnostic rates and reduced time to diagnosis ...
New offering integrates virtual clinicians to create a scalable channel to increase availability of GeneDx exome testing for eligible children facing specialty-care barriers
GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in upcoming investor conferences:...
Reported second quarter 2026 revenue of $114.4 million, including $100.3 million in exome and genome revenue Reported exome and genome volume growth of...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In GeneDx To Contact Him Directly To Discuss Their Options...
LOS ANGELES , Aug. 3, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS ) for violations...
LOS ANGELES , Aug. 3, 2026 /PRNewswire/ -- Schall Brown & Schwartz LLP , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GeneDx Holdings Corp....
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 3, 2026 ...
Barchart Research What to Expect from WGS Earnings WGS Generated July 31, 2026 Current Price $65.11 EPS Estimate $$-0.19 Consensus Rating Strong Buy Average Move 21.79% Can GeneDx Explain Why Its Blockbuster...